LACunar Intervention Trial-2 (LACI-2) featured in "The Scotsman"
An article about the second-largest study ever into lacunar strokes in a leading Scottish newspaper.
LACunar Intervention Trial-2 (LACI-2) was featured in "The Scotsman". The study aims to assess safety and efficacy of inexpensive and widely accessible medication: cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease. The research suggests that lacunar lesions could also be the underlying cause of nearly half of all dementias.
The study is funded by the British Heart Foundation and lead by Professor Joanna Wardlaw.
The study re-assumed recruiting participants after the break caused by the COVID-19 pandemic. Please, get in touch using the button below if you would like to participate in the study.
Read the article in "The Scotsman"
Article about LACunar Intervention Trial-2 (LACI-2) in "The Scotsman"
Related links
LACunar Intervention Trial-2 (LACI-2) website
Professor Joanna Wardlaw profile
Small Vessel Disease Research - publications